



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade: 144.94

Trade Time: 4:15 PM ET
Sep 25, 2017

Change: 1.05
(0.730%)

Day Range 143.70 - 146.13

52-Week Range 96.93 - 144.59

Volume 4,713,525

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Sep 8, 2017
[Data Presented at ESMO 2017 Further Evaluate Role of ABRAXANE® for Patients with Historically Challenging Cancers](#)

Sep 7, 2017
[Celgene Provides Update on the Fusion™ Clinical Program](#)

Aug 24, 2017
[Celgene Corporation to Webcast at Upcoming Investor Conferences](#)

Aug 1, 2017
[FDA Grants Approval of IDHIFA®@, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation](#)

Jul 28, 2017
[Celgene Corporation to Webcast at Upcoming Investor Conference](#)

Upcoming Events [\[View all \]](#)

Sep 26, 2017 9:45 AM ET
[Cantor Fitzgerald 3rd Annual Healthcare Conference](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

Feb 10, 2017
[Annual Report \(10-K\)](#)

Apr 27, 2017
[Proxy Statement \(DEF 14A\)](#)

Jul 27, 2017
[Quarterly Report \(10-Q\)](#)

Apr 27, 2017
[Quarterly Report \(10-Q\)](#)

Oct 27, 2016
[Quarterly Report \(10-Q\)](#)